The last week has been an eventful one for pharma stocks with Novartis NVSannouncing that it is acquiring gene therapy company AveXis while Merck MRKand AbbVie ABBVannounced successful study results. In other news, Pfizer’s PFEkidney cancer drug, Inlyta missed primary endpoint in a phase III study.
Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться